Zantrene: A brief review BackgroundZantrene is owned by Race...

Zantrene: A brief review

Background

Zantrene is owned by Race Oncology (RAC). Developed in the late 1970s to be an anthracycline that is safer for the heart, Zantrene was tested clinically through the 80s and 90s in a range of different blood and solid tumors. While not demonstrating strong clinical efficacy in solid tumors, Zantrene showed some promise in AML (Table 1), Follicular Lymphoma (ORR 56%; CR 31%; PR 25%; n = 16), and Breast cancer (1-4). The AML data led to the drug eventually being approved for use in France, but was never marketed. Due to a series of internal events, the drug was lost and never fully commercialized.

Table 1: A summary of AML trials

In 2016, RAC bought rights to the drug, and completed a P2 proof of concept trial, where there was a 40% ORR (1CR; 3PR) (5). Of the 10 heavily pretreated R/R AML patients, four were classified as extramedullary AML which was the patient population that achieved objective responses (100%). Figure 1 shows an excellent PET scan of a patient’s response to Zantrene.

Figure 1: PET scan of EMD AML patient treated with Zantrene

In 2020, the City of Hope discovered that Zantrene is in fact the most potent inhibitor of the m6A demethylase ‘Fat mass and obesity-associated protein’ or ‘FTO’ protein (6). The screening process investigated some ~250,000 different compounds within the library, and currently preclinical compounds are yet to match the potency of Zantrene for FTO (Table 2).

Table 2: Low nM concentration FTO targeting compounds

There has, therefore, been a shift in thinking regarding Zantrene as a safer anthracycline to the most potent FTO inhibitor, where all of the clinical data to date can and should be attributed to FTO inhibition over anthracycline activity. Looking through the lens of an FTO inhibitor highlights key pieces of preclinical and clinical data as well as challenges the preconceived notions surrounding Zantrene. Many lines of evidence support this line of thinking, which will be summarized herein.

1. https://www.raceoncology.com/wp-content/uploads/2020/08/the-rediscovery-of-bisantrene-a-review-of-the-literature-ijcrt-17-015.pdf
2. https://pubmed.ncbi.nlm.nih.gov/3581102/
3. https://pubmed.ncbi.nlm.nih.gov/3791560/
4. https://pubmed.ncbi.nlm.nih.gov/1875415/
5. https://pubmed.ncbi.nlm.nih.gov/33159365/
6. https://pubmed.ncbi.nlm.nih.gov/32531268/

Preclinical models supporting strong FTO inhibition and poor anthracycline activity

As previously mentioned, Zantrene is currently the most potent inhibitor of the FTO protein. Early preclinical models investigating Zantrene in comparison to other anthracyclines highlight the poor anthracycline activity of the drug. In historic preclinical studies conducted in the 80s, Zantrene was found to have IC50 values for anthracycline activity at uM concentrations, far greater than the nM concentrations achieved for FTO inhibition. In comparison to other approved Anthracyclines (Mitoxantrone & Doxorubicin) as well as compounds that did not achieve approval (Ametantrone), Zantrene was found to perform far worse in preclinical leukemia studies (1-2). If Zantrene was the worst performer of all drugs preclinically, then how was it able to achieve clinically relevant ORR rates that led to approval in France. Comparatively, Zantrene is roughly 126 times more potent at inhibiting FTO than functioning as an FTO inhibitor.

Figure 2: Zantrene (Bisantrene) demonstrating poor anthracycline activity

Further preclinical work has been completed by RAC to confirm the mechanism of action for Zantrene. A recent Melanoma publication showed that Zantrene can kill cells with a very low nM concentration and that the cell killing affinity correlated with FTO expression (Figure 3; 3). Also, further preclinical work into ccRCC demonstrated low nM cell killing in a range of different renal cell models (Figure 4; 4).

Figure 3: Melanoma Zantrene data

Figure 4: Summary of sensitivity of Zantrene to renal cell lines

1. https://pubmed.ncbi.nlm.nih.gov/4027978/
2. https://pubmed.ncbi.nlm.nih.gov/6850582/
3. https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02428461-09TIE9PC8M4UP8UMCSE73N1KTJ/pdf?access_token=0007HuJhseAUUhC12ZlEhQAzuY6O
4. https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02497549-2JQ1UC1MAC8L9I5V5CVRK309DN/pdf?access_token=0007HuJhseAUUhC12ZlEhQAzuY6O

Clinical data supporting FTO inhibition

I have made quite compelling summaries of the historic data and the possible influence of Zantrene as an FTO inhibitor in the following posts on social media. Put simply, there are some unusual findings when Zantrene is used; unlike the typical Anthracycline outcome. Without the FTO knowledge, these phenomena are difficult to explain, but when FTO inhibition is applied, I find there to be some interesting interpretations of the data.

https://hotcopper.com.au/threads/pillar-1-fto-new-thread.5839654/page-878?post_id=52698342

https://hotcopper.com.au/threads/pillar-1-fto-new-thread.5839654/page-1247?post_id=54368862

The FTO opportunity

I stopped gathering this data back in early February 2022, but there are 106 articles linking aberrant FTO expression to 28 different cancer types (Table 3) (1-106).

Table 3: Cancers linked to FTO expression

Additionally, there have been multiple papers that have found FTO inhibition synergies with roughly 16 different approved and unapproved chemotherapies (Table 4) (107-131), and FTO expression has been linked to a plethora of diseases including metabolic, neurological, and reproductive (Table 5) (132-217). This is likely due to the central role of FTO in regulating the intracellular methylation/demethylation of m6A mRNA and the cascading effects on genes, proteins, and thus, cellular function in a range of different cells.

Table 4: Summary of synergies with an FTO inhibitor

Table 5: Summary of diseases associated with aberrant FTO expression

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234852/
2. https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(20)30216-6
3. https://pubmed.ncbi.nlm.nih.gov/29249359/
4. https://www.researchsquare.com/article/rs-897609/v1
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812656/pdf/nihms-1053837.pdf
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058711/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218444/
8. https://www.frontiersin.org/articles/10.3389/fonc.2022.817584/
9. https://www.smartscitech.com/index.php/RD/article/view/246
10. https://www.nature.com/articles/s41467-021-22469-6.pdf
11. https://ashpublications.org/blood/article/134/Supplement_1/114/426565
12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714266/
13. https://www.smartscitech.com/index.php/RD/article/view/246
14. https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.310
15. https://www.aging-us.com/article/202359/pdf
16. https://www.mdpi.com/2673-7523/1/1/2
17. https://www.nature.com/articles/s41420-021-00724-5
18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938613/
19. https://pubmed.ncbi.nlm.nih.gov/30922314/
20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452952/
21. https://www.sciencedirect.com/science/article/pii/S2211383521003385
22. https://pubmed.ncbi.nlm.nih.gov/32089015/
23. https://academic.oup.com/bjs/article/108/Supplement_1/znab117.028/6255842
24. https://www.tandfonline.com/doi/full/10.1080/21655979.2021.1924544
25. https://www.researchgate.net/publication/358083969
26. https://pubmed.ncbi.nlm.nih.gov/32817424/
27. https://pubmed.ncbi.nlm.nih.gov/29315835/
28. https://pubmed.ncbi.nlm.nih.gov/31827395/
29. https://reader.elsevier.com/reader/sd/pii/S2372770521000991
30. https://www.sciencedirect.com/science/article/pii/S2372770521000991
31. https://www.researchgate.net/publication/349092260
32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218444/
33. https://pubmed.ncbi.nlm.nih.gov/33910046/
34. https://www.sciencedirect.com/science/article/pii/S0006291X20313711
35. https://pubmed.ncbi.nlm.nih.gov/33183350/
36. https://pubmed.ncbi.nlm.nih.gov/33533172/
37. https://www.frontiersin.org/articles/10.3389/fcell.2021.715674/full
38. https://www.europeanreview.org/wp/wp-content/uploads/8220-8226.pdf
39. https://pubmed.ncbi.nlm.nih.gov/22222214/
40. https://pubmed.ncbi.nlm.nih.gov/26884084/
41. https://pubmed.ncbi.nlm.nih.gov/33103587/
42. https://pubmed.ncbi.nlm.nih.gov/34347888/
43. https://pubmed.ncbi.nlm.nih.gov/32035950/
44. https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02096-1
45. https://www.researchsquare.com/article/rs-589523/v2
46. https://www.researchsquare.com/article/rs-907813/v1
47. https://www.researchgate.net/publication/337248777
48. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00648-1
49. https://www.nature.com/articles/s41388-021-01939-7
50. https://pubmed.ncbi.nlm.nih.gov/28849183/
51. https://www.sciencedirect.com/science/article/pii/S0024320521005075?via%3Dihub
52. https://www.nature.com/articles/s41417-020-0193-8
53. https://pubmed.ncbi.nlm.nih.gov/33393595/
54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086255/
55. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282183/
56. https://www.nature.com/articles/s41416-021-01581-w
57. https://www.nature.com/articles/s41419-022-04503-7
58. https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(20)30216-6
59. https://pubmed.ncbi.nlm.nih.gov/29249359/
60. https://pubmed.ncbi.nlm.nih.gov/28297667/
61. https://pubs.acs.org/doi/10.1021/acschembio.0c00841
62. https://pubmed.ncbi.nlm.nih.gov/32680921/
63. https://pubmed.ncbi.nlm.nih.gov/34390075/
64. https://www.nature.com/articles/s41598-019-49550-x
65. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332506/
66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235215/
67. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422133/
68. https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.24113
69. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627861/
70. https://www.frontiersin.org/articles/10.3389/fonc.2020.00718/full
71. https://pubmed.ncbi.nlm.nih.gov/34354868/
72. https://onlinelibrary.wiley.com/doi/10.1002/cam4.4188
73. https://atm.amegroups.com/article/view/81771/html
74. https://www.dovepress.com/the-rna-n6-methyladenosine-demethylase-fto-promotes-head-and-neck-squa-peer-reviewed-fulltext-article-IJGM
75. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789218/
76. https://pubmed.ncbi.nlm.nih.gov/33738268/
77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989706/
78. https://www.aging-us.com/article/203456/text
79. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213471/
80. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283020/
81. https://www.researchsquare.com/article/rs-778749/v1
82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565892/pdf/ijgm-14-7411.pdf
83. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035887/
84. https://pubmed.ncbi.nlm.nih.gov/30905413/
85. https://www.sciencedirect.com/science/article/abs/pii/S0006291X1831252X
86. https://www.frontiersin.org/articles/10.3389/fonc.2021.763027/full
87. https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00061-9
88. https://www.biorxiv.org/content/10.1101/2021.07.06.451216v1.full.pdf
89. https://www.hindawi.com/journals/ecam/2021/1436088/
90. https://www.jbc.org/action/showPdf?pii=S0021-9258%2822%2900003-5
91. https://www.nature.com/articles/s41467-019-10669-0
92. https://pubmed.ncbi.nlm.nih.gov/33910046/
93. https://assets.researchsquare.com/files/rs-983314/v1/09f8aafb-8360-4f60-97ae-e7526cb3372c.pdf?c=1634843062
94. https://www.nature.com/articles/s41388-022-02214
95. https://pubmed.ncbi.nlm.nih.gov/32825930/
96. https://atm.amegroups.com/article/view/87556/pdf
97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548690/
98. https://pubmed.ncbi.nlm.nih.gov/30719115/
99. https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(20)30216-6
100. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08550-9
101. https://pubmed.ncbi.nlm.nih.gov/34744452/
102. https://cancerres.aacrjournals.org/content/79/13_Supplement/179
103. https://www.nature.com/articles/s41388-021-01820-7
104. https://onlinelibrary.wiley.com/doi/10.1002/cam4.4188
105. https://pubmed.ncbi.nlm.nih.gov/34779644/
106. https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-02090-9
107. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136921/
108. https://www.nature.com/articles/s41467-019-10669-0
109. https://www.sciencedirect.com/science/article/pii/S0006291X20313711
110. https://www.sciencedirect.com/science/article/abs/pii/S1535610820302166
111. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218444/
112. https://mcr.aacrjournals.org/content/early/2021/02/09/1541-7786.MCR-20-0541
113. https://pubmed.ncbi.nlm.nih.gov/29315835/
114. https://pubmed.ncbi.nlm.nih.gov/32680921/
115. https://jeccr.biomedcentral.com/track/pdf/10.1186/s13046-021-01942-6.pdf
116. https://onlinelibrary.wiley.com/doi/10.1002/cam4.4188
117. https://www.cell.com/cancer-cell/pdfExtended/S1535-6108(20)30216-6
118. https://pubmed.ncbi.nlm.nih.gov/29249359/
119. https://pubmed.ncbi.nlm.nih.gov/29315835/
120. https://portlandpress.com/bioscirep/article/41/1/BSR20200842/227460/Omeprazole-improves-chemosensitivity-of-gastric
121. https://www.biorxiv.org/content/10.1101/2021.01.12.426354v1.full.pdf
122. https://www.raceoncology.com/md-anderson-cancer-center-researchers-publish-aml-preclinical-study-on-bisantrene-drug-combinations/
123. https://pubmed.ncbi.nlm.nih.gov/29249359/
124. https://www.raceoncology.com/md-anderson-cancer-center-researchers-publish-aml-preclinical-study-on-bisantrene-drug-combinations/
125. https://pubmed.ncbi.nlm.nih.gov/8259097/
126. https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02463955-1DOHC0VF6VO6KDECS48J2FT4LV/pdf?access_token=0007UA1Q914uMqat2flB1pWo6Lv5
127. https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2042689?needAccess=true
128. https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2042689?needAccess=true
129. https://pubmed.ncbi.nlm.nih.gov/29249359/
130. https://www.nature.com/articles/s43018-021-00223-7
131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343999/#SM0
132. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658005/
133. https://pubmed.ncbi.nlm.nih.gov/20943749/
134. https://pubmed.ncbi.nlm.nih.gov/29456697/
135. https://www.mdpi.com/2072-6643/13/5/1683
136. https://pubmed.ncbi.nlm.nih.gov/19005641/
137. https://pubmed.ncbi.nlm.nih.gov/30137347/
138. https://pubmed.ncbi.nlm.nih.gov/25303482/
139. https://pubmed.ncbi.nlm.nih.gov/30170548/
140. https://pubmed.ncbi.nlm.nih.gov/28603074/
141. https://www.sciencedirect.com/science/article/pii/S1319562X21004617#!
142. https://www.sciencedirect.com/science/article/pii/S0039128X21001094
143. https://link.springer.com/article/10.1007/s13410-021-00974-0
144. https://pubmed.ncbi.nlm.nih.gov/17496892/
145. https://pubmed.ncbi.nlm.nih.gov/19234441/
146. https://pubmed.ncbi.nlm.nih.gov/25881961/
147. https://pubmed.ncbi.nlm.nih.gov/25412662/
148. https://pubmed.ncbi.nlm.nih.gov/24518103/
149. https://science.sciencemag.org/content/372/6546/1085
150. https://pubmed.ncbi.nlm.nih.gov/27827997/
151. https://pubmed.ncbi.nlm.nih.gov/21919686/
152. https://pubmed.ncbi.nlm.nih.gov/27324062/
153. https://pubmed.ncbi.nlm.nih.gov/23867619/
154. https://pubmed.ncbi.nlm.nih.gov/28267420/
155. https://pubmed.ncbi.nlm.nih.gov/34364300/
156. https://pubmed.ncbi.nlm.nih.gov/30305247/
157. https://pubmed.ncbi.nlm.nih.gov/29795461/
158. https://link.springer.com/article/10.1007/s10528-021-10079-2
159. https://pubmed.ncbi.nlm.nih.gov/19053021/
160. https://pubmed.ncbi.nlm.nih.gov/19073975/
161. https://pubmed.ncbi.nlm.nih.gov/23329013/
162. https://pubmed.ncbi.nlm.nih.gov/24410832/
163. https://pubmed.ncbi.nlm.nih.gov/27651333/
164. https://pubmed.ncbi.nlm.nih.gov/29384213/
165. https://pubmed.ncbi.nlm.nih.gov/22608085/
166. https://pubmed.ncbi.nlm.nih.gov/26078098/
167. https://pubmed.ncbi.nlm.nih.gov/33817272/
168. http://www.ijcem.com/files/ijcem0028249.pdf
169. https://pubmed.ncbi.nlm.nih.gov/28116842/
170. https://pubmed.ncbi.nlm.nih.gov/32848374/
171. https://pubmed.ncbi.nlm.nih.gov/32116145/
172. https://pubmed.ncbi.nlm.nih.gov/29924135/
173. https://link.springer.com/article/10.1007%2Fs13577-021-00593-1
174. https://pubmed.ncbi.nlm.nih.gov/33914321/
175. https://pubmed.ncbi.nlm.nih.gov/32050935/
176. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160584/
177. https://pubmed.ncbi.nlm.nih.gov/20092643/
178. https://pubmed.ncbi.nlm.nih.gov/29463151/
179. https://link.springer.com/article/10.1007/s43032-021-00664-6
180. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016779/
181. https://pubmed.ncbi.nlm.nih.gov/33876670/
182. https://pubmed.ncbi.nlm.nih.gov/31801409/
183. https://pubmed.ncbi.nlm.nih.gov/32984346/
184. https://pubmed.ncbi.nlm.nih.gov/34496349/
185. https://pubmed.ncbi.nlm.nih.gov/34469786/
186. https://pubmed.ncbi.nlm.nih.gov/29501742/
187. https://www.researchgate.net/publication/314429110
188. https://pubmed.ncbi.nlm.nih.gov/21098976/
189. https://pubs.acs.org/doi/10.1021/acschemneuro.1c00063
190. https://pubmed.ncbi.nlm.nih.gov/30835997/
191. https://pubmed.ncbi.nlm.nih.gov/33805312/
192. https://pubmed.ncbi.nlm.nih.gov/23817550/
193. https://pubmed.ncbi.nlm.nih.gov/26354923/
194. https://pubmed.ncbi.nlm.nih.gov/33926120/
195. https://pubmed.ncbi.nlm.nih.gov/28282466/
196. https://www.biorxiv.org/content/10.1101/623728v1
197. https://pubmed.ncbi.nlm.nih.gov/23512716/
198. https://pubmed.ncbi.nlm.nih.gov/20186806/
199. https://pubmed.ncbi.nlm.nih.gov/30048615/
200. https://pubmed.ncbi.nlm.nih.gov/28205605/
201. https://pubmed.ncbi.nlm.nih.gov/27335407/
202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376469/
203. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537566/
204. https://pubmed.ncbi.nlm.nih.gov/21502950/
205. https://www.nature.com/articles/mp20144
206. https://pubmed.ncbi.nlm.nih.gov/33939949/
207. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145299/
208. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6576176/
209. https://pubmed.ncbi.nlm.nih.gov/33829413/
210. https://pubmed.ncbi.nlm.nih.gov/32670741/
211. https://pubmed.ncbi.nlm.nih.gov/33995105/
212. https://pubmed.ncbi.nlm.nih.gov/34130310/
213. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301379/
214. https://pubmed.ncbi.nlm.nih.gov/28073764/
215. https://pubmed.ncbi.nlm.nih.gov/24532085/
216. https://pubmed.ncbi.nlm.nih.gov/31836807/
217. https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkac062/6524254?rss=1#331394133

Summary

I’m sure you can agree that Zantrene is a very interesting molecule in a developing space. This review has not included the cardioprotection aspect of Zantrene, as that work is in its infancy, and deserves its own independent review. I am looking forward to the RAC team determining and developing the dose, dosing regimen, patient population, screening tool, and clinical data supporting FTO in humans, as it is currently in its infancy. At the very least, I hope that you found this information interesting.